Physician profile
Moshe E Hirth
NPI 1740374677
$3,713.29
in general payments reported to CMS, 2019-2025
25 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $737 · 2020: $182 · 2021: $635 · 2022: $890 · 2023: $678 · 2024: $395 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,269.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $712.11 | 2019-2024 | Stelara, Remicade, Simponi Aria |
| Abbvie INC. | $607.17 | 2019-2024 | |
| Gilead Sciences, INC. | $372.63 | 2019-2025 | |
| Braintree Laboratories, INC. | $261.91 | 2019-2025 | Sutab, Suflave |
| Celgene Corporation | $256.08 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $240.88 | 2019-2025 | Entyvio, Eohilia |
| Merck Sharp & Dohme LLC | $232.76 | 2019-2023 | Dificid |
| Medtronic, INC. | $210.30 | 2022-2023 | Interstim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $190.50 | 2019-2024 | Trulance, Xifaxan |
| Ardelyx, INC. | $95.78 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $72.86 | 2019-2024 | |
| Pfizer INC. | $70.00 | 2023-2024 | |
| Cumberland Pharmaceuticals, INC. | $54.02 | 2023 | Kristalose |
| Allergan, INC. | $50.76 | 2019 | |
| Novo Nordisk INC | $44.42 | 2025 | Wegovy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $38.49 | 2019-2020 | |
| Alfasigma USA, INC. | $37.42 | 2020 | |
| Genzyme Corporation | $28.28 | 2023 | |
| Redhill Biopharma INC. | $24.65 | 2021 | |
| Davol INC. | $24.54 | 2021 | |
| Aimmune Therapeutics, INC. | $22.31 | 2025 | Vowst |
| Shionogi INC | $20.05 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.36 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.74 | 2023 | Dupixent |
| Vivus LLC | $14.27 | 2024 | Pancreaze |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moshe Hirth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.